GSK weighing scrapping investor payout to boost dividend instead

Analysts are suggesting that GlaxoSmithKline ($GSK) is thinking hard about scrapping a plan to reward investors by paying them about £4 billion and instead use money from its deals with Novartis ($NVS) to prop up its dividend, Reuters reports. Last year the British drugmaker said that when it finished up the asset swaps with Novartis it would use a B share disbursement to pay them about £4 billion of the proceeds. But with its 5% dividend under pressure, analysts at Goldman Sachs and Berenberg Bank think that plan has "stalled" and it might use the money to provide confidence in its shares. Story

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…